Haemonetics Stock

Haemonetics EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Haemonetics (HAE) as of Aug 5, 2026 is 11.12. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 12.10 — a change of -8.11% (lower).

EV/EBIT

11.12

YoY

-8.11%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Haemonetics is 2026 11.12 . EV/EBIT (Enterprise Value to EBIT) of Haemonetics was 2025 12.10 . It decreases by -8.11% lower compared to the previous year.

The Haemonetics EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
45.34 base
Jan 1, 2020
32.57 base
Jan 1, 2021
30.34 base
Jan 1, 2022
49.89 base
Jan 1, 2023
28.19 base
Jan 1, 2024
23.98 base
Jan 1, 2025
16.98 base
Jan 1, 2026
16.53 base
YEARPRICE-TO-EBIT
2026 16.53
2025 16.98
2024 23.98
2023 28.19
2022 49.89
2021 30.34
2020 32.57
2019 45.34
2018 55.60
2017 50.21
2016 -30.43
2015 25.76
2014 26.23
2013 25.03
2012 15.45
2011 4.51
2010 6.20
2009 5.34
2008 6.70
2007 8.50
Access this data via the Eulerpool API

Haemonetics Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Haemonetics's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Haemonetics's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Haemonetics's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Haemonetics grows earnings faster than its peers.

Haemonetics Stock analysis

What does Haemonetics do? Haemonetics Corp is a leading provider of blood processing and transfusion products. The company was founded in 1971 by Dr. Jack Latham to create a better solution for the storage and transfer of blood products. Since then, the company has become a major provider of products and services for the blood transfusion industry. Haemonetics' business model is focused on the development, manufacturing, and marketing of products and devices for blood transfusion. The company offers a wide range of products and services, including blood processing systems, blood collection and maintenance devices, software solutions, blood components, and related accessories. In recent years, Haemonetics has dedicated itself to diversifying its offerings. While still focusing on the blood transfusion industry, the company has also expanded into other areas, such as the treatment of patients with blood disorders and the development of devices for cell therapy. Haemonetics is divided into various business segments, including Blood Management Solutions, Diagnostic Solutions, and Haemonetics Software Solutions. The Blood Management Solutions segment includes a range of products, including blood collection and storage devices, centrifuges, and hematocrit systems. Diagnostic Solutions provides diagnostic tests for blood disorders, including tests for coagulation disorders and thrombophilia. Haemonetics Software Solutions offers software solutions for the blood transfusion industry, including systems for automated processing and storage of blood products, as well as systems for automatic inventory management. Haemonetics' products also include devices for freezing blood products and for processing blood components. These devices help ensure that blood products are stored at optimal temperatures and conditions to ensure their effectiveness and usability for the patient. Another important area of Haemonetics' business is the development of devices for cell therapy. The company works closely with research institutes and biotech companies to develop innovative technologies for cell therapy. This includes the development of devices for the isolation and purification of stem cells that can be used for the treatment of cancer and other diseases. Haemonetics Corp has made a name for itself in the blood transfusion industry and continues to focus on innovation and diversification to fully utilize the potential of the company and its products. With a wide range of products and services, a strong commitment to research and development, and an unwavering focus on the needs of patients and healthcare providers, Haemonetics is well positioned to continue growing and expanding in the future. Haemonetics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Haemonetics stock

EV/EBIT (Enterprise Value to EBIT) of Haemonetics is 11.12 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Haemonetics changed from 12.10 to 11.12, representing a -8.11% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Haemonetics since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Haemonetics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Haemonetics

All Key Metrics — Haemonetics